Blog
Cardiometabolic Case Studies using OMOP CDM
Katarzyna Grzeslak, MA
Feb 11, 2025

All cases leverage the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) to analyse large-scale healthcare data for real-world evidence (RWE).

Case 1: Dual-Agent Anti-Hypertensive Drug

  • Challenge: Pharmaceutical company needed additional evidence to support a new dual-agent anti-hypertensive drug for a quick EMA (European Medicines Agency) bid resubmission.
  • Solution: Analysed electronic medical records (EMR) from Germany and France using OMOP to show the drug's effectiveness in reducing blood pressure.
  • Impact: Results supported the drug's bid and highlighted the benefits of OMOP for fast turnaround projects.

Case 2: Menopausal Women and Vasomotor Symptoms

  • Challenge: Characterize menopausal patient populations for a client's RWE study.
  • Solution: Leveraged the OHDSI network and OMOP to analyse data from multiple databases for a comprehensive characterization.
  • Impact: Identified thiazide diuretics as the most effective first-line anti-hypertensive drugs compared to ACE inhibitors. This study led to a publication in The Lancet and established a framework for future network studies.

Case 3: Incidence of Adverse Cardiovascular Events in patients with acute myocardial infarction

  • Challenge: A pharmaceutical company needed real-world data on adverse cardiovascular events after a heart attack to support their novel cardiovascular therapy.
  • Solution: Analysed data from the US PharMetrics Plus database using OMOP to identify risk factors for adverse events after a heart attack.
  • Impact: Results complemented ongoing clinical trials by characterizing real-world incidence rates and informing future work for the client.

Case 4: LEGEND Hypertension

  • Challenge: Determine the optimal first-line therapy for hypertension with limited data on comparative effectiveness.
  • Solution: Analysed data from multiple databases in the OHDSI network using OMOP to compare the effectiveness and safety of different anti-hypertensive drug classes.
  • Impact: Identified thiazide diuretics as the most effective first-line treatment and established a framework for future large-scale network studies in other therapeutic areas.

Case 5: Predicting Future Cost Burden in T2DM

  • Challenge: A pharmaceutical company wanted to understand which patients with type 2 diabetes mellitus (T2DM) would benefit most from their drug to inform future clinical trials.
  • Solution: Analysed data from multiple databases using OMOP to develop a model predicting high-cost T2DM patients.
  • Impact: Insights helped the client design future clinical trials to target patients most likely to benefit from their drug.

Case 6: Large-Scale Analysis of Dual Combination Therapies for Hypertension

  • Challenge: Lack of data on clinical use patterns of dual combination therapies for hypertension.
  • Solution: Analysed data from 11 databases across 8 countries using the federated network model of OHDSI.
  • Impact: Identified significant variation in dual combination therapy use across countries and demographics, highlighting the need for more standardized treatment patterns.

Key Takeaways:

  • OMOP allows for standardized analysis of healthcare data from various sources, increasing analytical power.
  • It facilitates real-world evidence generation for quicker regulatory processes and drug development.
  • The OHDSI network provides collaborative tools and expertise for large-scale studies.
  • OMOP findings can inform clinical trial design, marketing strategies, and healthcare resource allocation.

Related solutions

Contact Us